{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04721418",
            "orgStudyIdInfo": {
                "id": "2000029552"
            },
            "secondaryIdInfos": [
                {
                    "id": "1R01DA052454-01A1",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/1R01DA052454-01A1"
                }
            ],
            "organization": {
                "fullName": "Yale University",
                "class": "OTHER"
            },
            "briefTitle": "Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study",
            "officialTitle": "Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study",
            "therapeuticArea": [
                "Other"
            ],
            "study": "aberrant-synaptic-plasticity-in-cocaine-use-disorder-a-ucb-j-pet-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-07-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-01-14",
            "studyFirstSubmitQcDate": "2021-01-21",
            "studyFirstPostDateStruct": {
                "date": "2021-01-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-02",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Yale University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research study is to measure synaptic density in the brain comparing individuals with cocaine use disorder to healthy controls.",
            "detailedDescription": "Healthy controls (HC) will be studied as outpatient and undergo one MRI and one 11C-UCB-J PET scan along with neurocognitive tasks. Individuals with Cocaine Use Disorder (CUD) will complete the study as inpatients on our unit and undergo one MRI and two 11C-UCB-J PET scan along with neurocognitive tasks. Cocaine users will be asked to complete outpatient follow-ups twice a week for up to nine weeks following their inpatient stay."
        },
        "conditionsModule": {
            "conditions": [
                "Cocaine Use Disorder",
                "Healthy Controls"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "CROSS_SECTIONAL"
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cocaine Use Disorder",
                    "interventionNames": [
                        "Radiation: 11C-UCB-J"
                    ]
                },
                {
                    "label": "Healthy Control",
                    "interventionNames": [
                        "Radiation: 11C-UCB-J"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "RADIATION",
                    "name": "11C-UCB-J",
                    "description": "11C-UCB-J PET scan",
                    "armGroupLabels": [
                        "Cocaine Use Disorder",
                        "Healthy Control"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Between-group (CUD vs. HC) comparisons in ACC.",
                    "description": "Between-group comparisons of the fP-corrected total volume of distribution (VT/fP) in ACC.",
                    "timeFrame": "CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient."
                },
                {
                    "measure": "Between-group (CUD vs. HC) comparisons in vmPFC.",
                    "description": "Between-group comparisons of the fP-corrected total volume of distribution (VT/fP) in vmPFC.",
                    "timeFrame": "CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient."
                },
                {
                    "measure": "Between-group (CUD vs. HC) comparisons in mOFC.",
                    "description": "Between-group comparisons of the fP-corrected total volume of distribution (VT/fP) in mOFC.",
                    "timeFrame": "CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Within subjects (CUD group) comparisons in ACC.",
                    "description": "Within subjects (CUD group) comparisons (i.e., baseline/pre-abstinence vs. after 3 weeks of inpatient abstinence) of the fP-corrected total volume of distribution (VT/fP) in ACC.",
                    "timeFrame": "Baseline versus 3 weeks after."
                },
                {
                    "measure": "Within subjects (CUD group) comparisons in vmPFC.",
                    "description": "Within subjects (CUD group) comparisons (i.e., baseline/pre-abstinence vs. after 3 weeks of inpatient abstinence) of the fP-corrected total volume of distribution (VT/fP) in vmPFC.",
                    "timeFrame": "Baseline versus 3 weeks after."
                },
                {
                    "measure": "Within subjects (CUD group) comparisons in mOFC.",
                    "description": "Within subjects (CUD group) comparisons (i.e., baseline/pre-abstinence vs. after 3 weeks of inpatient abstinence) of the fP-corrected total volume of distribution (VT/fP) in mOFC.",
                    "timeFrame": "Baseline versus 3 weeks after."
                },
                {
                    "measure": "Between-group (CUD vs. HC) of volume of distribution comparisons in ACC.",
                    "description": "Between-group comparisons of volume of distribution (VT) in ACC.",
                    "timeFrame": "CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient."
                },
                {
                    "measure": "Between-group (CUD vs. HC) of volume of distribution comparisons in vmPFC.",
                    "description": "Between-group comparisons of volume of distribution (VT) in vmPFC.",
                    "timeFrame": "CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient."
                },
                {
                    "measure": "Between-group (CUD vs. HC) of volume of distribution comparisons in mOFC.",
                    "description": "Between-group comparisons of volume of distribution (VT) in mOFC.",
                    "timeFrame": "CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient."
                },
                {
                    "measure": "Between-group (CUD vs. HC) comparisons of binding potential in ACC.",
                    "description": "Between-group comparisons of binding potential (BPND) in ACC.",
                    "timeFrame": "CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient."
                },
                {
                    "measure": "Between-group (CUD vs. HC) comparisons of binding potential in vmPFC.",
                    "description": "Between-group comparisons of binding potential (BPND) in vmPFC.",
                    "timeFrame": "CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient."
                },
                {
                    "measure": "Between-group (CUD vs. HC) comparisons of binding potential in mOFC.",
                    "description": "Between-group comparisons of binding potential (BPND) in mOFC.",
                    "timeFrame": "CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient."
                },
                {
                    "measure": "Between-group (CUD vs. HC) comparisons of gray matter volume in ACC.",
                    "description": "Between-group comparisons of gray matter volume (GMV) in ACC.",
                    "timeFrame": "CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient."
                },
                {
                    "measure": "Between-group (CUD vs. HC) comparisons of gray matter volume in vmPFC.",
                    "description": "Between-group comparisons of gray matter volume (GMV) in vmPFC.",
                    "timeFrame": "CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient."
                },
                {
                    "measure": "Between-group (CUD vs. HC) comparisons of gray matter volume in mOFC.",
                    "description": "Between-group comparisons of gray matter volume (GMV) in mOFC.",
                    "timeFrame": "CUD: After 3 weeks of inpatient abstinence. HC: At baseline as outpatient."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 21-60 years\n* Physically healthy by medical history, physical, neurological, ECG and laboratory examinations\n* For females, a negative serum pregnancy test\n* For CUD: DSM-5 criteria for Cocaine Use Disorder and positive urine toxicology showing recent use\n* For HC: Negative urine toxicology\n\nExclusion Criteria:\n\n* DSM-5 criteria for other substance use disorders (e.g., alcohol, opiates, sedative hypnotics), except for nicotine\n* A primary DSM-5 Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the Structured Clinical Interview for DSM-5 (SCID-5)\n* A history of significant and/or uncontrolled medical or neurological illness\n* Current use of psychotropic and/or potentially psychoactive prescription medications\n* Medical contraindications to MRI procedure",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "maximumAge": "60 Years",
            "stdAges": [
                "ADULT"
            ],
            "studyPopulation": "One group will have current Cocaine Use Disorder, the other group will be Healthy Controls",
            "samplingMethod": "PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Marcella Mignosa, MD",
                    "role": "CONTACT",
                    "phone": "203 974 7557",
                    "email": "marcella.mignosa@yale.edu"
                }
            ],
            "locations": [
                {
                    "facility": "Connecticut Mental Health Center",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06519",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gustavo Angarita, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M6271",
                    "name": "Cocaine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "VaCoAg",
                    "name": "Vasoconstrictor Agents"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}